DOCSLIB.ORG

FAST TOXICOLOGICAL SCREENING KIT by LC-MS/MS – Code SC9000U

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FAST TOXICOLOGICAL SCREENING KIT by LC-MS/MS – Code SC9000U FAST TOXICOLOGICAL SCREENING KIT BY LC-MS/MS – Code SC9000U The kit for the toxicological-forensic analysis is a screening method to analyze hundreds of compounds in positive and negative mode in urine. It is possible to determine the following molecules: POSITIVE MODE: Amitrole Alypin Bamifylline 17 -alpha -Methyltestosterone Amantadine Bamipin 2-Amino -5-chlorobenzophenone Ambroxol Beclamide 2-Amino -5-nitrobenzophenone Ambucetamide Beclometasone dipropionate 2-Hydroxyethylflurazepam Amezinium Befunolol 3,4 -Methylenedioxyamphetamine Amidopyrin Bendiocarb 3,4 -Methylenedioxyethylamphetamine Amidotrizoic Acid Benfluorex 3,4 -Methylenedioxymethamphetamine Amiloride Benodanil 3,5 -Diiodo tyrosine Aminodantrolene Benperidole 4-Benzamidosalicyclic acid Aminoglutethimide Benproperine 6-Mercaptourine Aminophenazone Bensultap 6-O-Monoacetylmorphine Aminopromazine Bentiromide 7-Aminoclonazepam Aminorex Benzatropine 7-Aminodesmethylflunitrazepam Amiodarone Benzocaine 7-Aminoflunitrazepam Amiphenazole Benzoctamine 7-Aminonitrazepam Amisulpride Benzododec inium 9-Hydroxyrisperidone Amitr iptylin Benzoylecgonine cebutolol Amlodipine Benzthiazuron Aceclidine Ammoidin Berberine Aceclofenac Amorolfine Betamethasone 21 -phosphate Acemetacin Amoxicillin Betaxolol Acepromazine Amphetamine Bevonium Ac eprometazine Amrinone Bezafibrate Acetiamin Antazoline Biperiden Acetylaminonitroprophoxybenzene Apalcillin Bisoprolol Aciclovir Apomorphine Bornaprine Actinoquinol Apophedrin Brodifacoum Adenine Apraclonidin Bromacil Adrenalone Aprinidine Bromazepam Ajmaline Atenolol Bromocriptine Alachlor Atorvastatin Brompheniramine Alclometasone -17,21 -dipropionate Atraton Brotizolam Alimemazine Atrazine -desethyl Bucetin Alizapride Atropine Bufexamac Allopurinol Atropinmethylbromid Bumetanide Almitrine Azatadine Bunazosin alpha -Hydroxyalprazolam Azelasti ne Bunitrolol alpha -Hydroxytriazolam Azintamid Bupivacaine Alprazolam Aztreonam Bupranolol Alprenolol Baclofen Buprenorphine Altretamine Bambuterol Buprofezin 1 Buspirone Clobenzepam Dienogest Butaperazine Clobutinol Diethazine Butetamate Clomethiazole Diethylcarbamazine Butoxycaine Clomipramine Difenoconazole Cafaminol Clonazepam Difenoxuron Caffeine Clonidine Diflucortolone Candesartan Clopenthixol Dihydrocodeine Caproylresorcinol Clopidogrel Dihydroergocristin Captopril Cloprednol Dihydroergotamine Carazolol Clozapine Dilazep Carbamazepine Cocaine Diltiazem Carbamazepine 10,11 -epoxide Codeine Dimetindene Carbendazi m Coniine Dimetotiazine Carbinoxamine Corticosterone Dimetridazole Carbutamide Cortisone Dioxethedrin Carbuterol Cotinine Diphenamid Carteolol Coumatetralyl Diphenhydramine Carvedilol Croconazole Diponium Celiprolol Cromoglicic acid Diprophylline Cerivastatin Cyamemazine Dipyridamole Cetirizine Cyclicine Disopyramide Chinine Cyclophosphamide Dixyrazine Chlorazanil Cyclovalone Dobutamine Chlorbenzoxamine Cyp roheptadine Dorzolamide Chlorcyclizine Cytarabine Doxapram Chlordiazepoxide D3 -Doxepin Doxepin Chloridazon D5 -Diazepam Doxylamine Chlormadinone Acetate Dapiprazole Drofenine Chlormequat Deflazacort Dummy Chlorphenethiazine Demeton -S-methylsulfone Ecgonineme thylester Chlorphen iramine Denaverine EDDP Chlorpromazine Desalkylflurazepam Embutramide Chlorpromazine Sulfoxide Desipramine Enalapril Chlorprothixene Desmedipham Enoximone Cilastatin Desmethylclobazam Ephedrine Cilazapril Desmethylclomipramine Eprosartan Cimetidine Dexamethasone Esculin Cinnarizine Dexamethasone 21 -isonicotinate Esmolol Cinoxacin Dexfenfl uramine Estazolam Ciprofloxacin Dextromethorphan Ethenzamide Cisapride Dextropropoxyphene Etofenamate Citalopram Diaveridine Etomidate Clarithromycin Diazepam Etoposide Clemastine Dibutyl adipate Famotidine Clenbuterol Diclofenac Fedrilate Clobazam Dicycloverine Felbamate 2 Felodipine Guanoxan Lisinopril Fenarimol Haloperidol Lonazolac Fendiline Haloxyfop ethoxyethyl ester Loperamide Fenetylline Heptaminol Loratadine Fenfluramine Heroin Lorazepam Fenpipram ide Hexazinone Lormetazepam Fenpiprane Hexobendine Losartan Fenproporex Histamine Loxapine Fentanyl Histapyrrodine Lysergide Fenticonazole Homatropine Mafenide Fexofenadine Hordenine Maprotiline Flecainide Hydrocodone MBDB Flocoumafen Hydrocortisone Meb everine Floctafenine Hydrocortisone 21 -acetate Meclizine Fluanisone Hydromorphone Meclofenamic acid Fluconazole Hydroxyzine Mecloxamine Flumazenil Hym ecromone Meclozine Flunarizine Imipramine Medazepam Flunitrazepam Indanazoline Mefenamic acid Fluoxetine Indapamine Mefenorex Flupentixol Indinavir Mefexamide Fluphenazine Indoprofen Mefloquine Flupirtine Indoramin Melatonin Flurazepam Iopodic acid Melitracen Flurochloridone Ipratropium Meloxicam Flu spirilen Iprazochrome Melperone Fluticasone Propionate Irbesartan Melphalan Fluvastadine Isoaminile Mepindolol Fluvoxamine Isoconazole Mepivacaine Fuberidazole Isoprenaline Meptazinol Furalaxyl Isoproturon Mequitazine Gabapentin Isothipendyl Mescaline Galantamine Isoxicam Mesoridazine Gallopamil Isoxsuprine Mesuximide Gemcitabine Kavain Metaclazepam Glibenclamide Ketamine Metamfepramone Glibornuride Ketoprofen Metamitron Gliclazide Ke torolac Metamphetamine Glimepiride Ketotifen Metazachlor Glipizide Lamotrigine Metenolone acetate Gliquidone Lercanidipine Metformin Griseofulvin Levocabastine Methabenzthiazuron Guaifenesin Levodopa Methadone Guanabenz Levomepromazine Methaphenilene Guane thidine Levopropylhexedrin Methapyrilene Guanfacine Lidocaine Methaqualon 3 Methazolamide Nebivolol Oxilofrine Methfuroxam Nefopam Oxitriptan Methocarbamol Nicardipine Oxitropium Methoprotryne Nicotinamide Oxomemazine Methotrex ate Nicotine Oxprenolol Methylephedrine Nifedipine Oxybuprocaine Methylphenidate Nifenazone Oxybutynin Methylscopolamine Niflumic acid Oxycodone Methylthiouracil Nimodipine Oxyfedrine Metipranolol Nimorazole Oxymetazoline Metixene Nisoldipine Oxymorphon Metoprolol N-Isopropylsalicylamide Oxypertine Metronidazole Nitrazepam Papaverine Metsulfuron -methyl Nitrendipine Paracetamol Metyrapone Nizatidine Paraoxon Mexiletine N-Methylephed rine Paroxetine Mianserin Nomifensine Penfluridol Miconazole Norbuprenorphine Pentamidine Midazolam Nordiazepam Pentoxyverine Midodrine Nordiazepam N -ethyl Perazine Milrinone Norephedrine Periciazine Minoxidil Norethisterone Perindopril Mirtazapine Norethisterone acetate Perphenazine Mizol astine Norfenefrine Pethidine Moclobemide Norfentanyl Phenacetin Modafinil Norfloxacin Phenazone Molsidomine Normorphine Phenazopyridine Monocrotophos Nortriptyline Phencyclidine Monolinuron Noscapine Phenelzine Moperone Nuarimol Pheniramine Morphine Obidoxime Phenprocoumon Morphine -3-ß-D-glucuronide Ofloxacin Phenylephrine Moxaverine Olanzapine Phenyltoloxamine Moxisylyte Ondanset ron Phenytoin Moxonidine Opipramol Pholedrine Nabumetone Orciprenaline Physostigmine Nadolol Ornidazole Pilocarpine Naftidrofuryl Orphenadrine Pindolol Naftifine Oxadixyl Pioglitazone Nalidixic acid Oxamyl Pipamperone Nalorphine Oxatomide Pirbuterol Naloxone Oxazepam Pirenzepine Naltrexone Oxcarbazepine Piretanide Na ndrolone Oxeladin Piritramide Naphazoline Oxetacaine Piroxicam N-Despropylpropafenone Oxiconazole Pizotifen 4 Practolol Risperidone Tetroxoprim Prajmalium Ritodrine Tetryzoline Pramipexole Rizatriptan THC Prazepam Ropinirole THC -COOH Prazosin Ropivacaine THC -OH Prednisolone Rosiglitazon Thebacon Prednisone Salbutamol Theobromine Prilocaine Salicylamide Theophylline Primaquine Scopolamine Thiabendazole Primidone Serotonin Thiamazole Procainamide Sertindole Thiamine Prochlorperazine Sertraline Thiopropazate Procyclidine Sildenafil Thioprop erazine Progesterone Simazine Thioridazine Promazine Sotalol Thiram Promethazin Spirapril Tiagabine Prometryn Stanozolol Tiapride Propafenone Sulfabenza mide Ticlopidine Propiconazole Sulfadiazine Tiemonium Propionylpromazine Sulfadoxine Tilidine Propipocaine Sulfaethidole Timolol Propiverine Sulfaguanidine Tinidazole Prop ranolol Sulfamethizole Tizanidine Propyphenazone Sulfamethoxazole Tocainide Prothiopendyl Sulfapyridine Tolazoline Protriptyline Sulfaquinoxaline Tolbutamide Pseudoephedrine Sulindac Toliprolol Psilocin Sulpiride Tolnaftate Pyranocoumarin Sultiame Tolpropamine Pyribenzamine Sumatriptan Tolycaine Pyridoxine Suxibuzone Topotecan Pyrimethamine Tadalafil Torasemide Pyritinol Talinolol Tramadol Pyrvinium Tamoxifen Tranexamic acid Quetiapine Telmisartan Tr azodone Quinapril Temazepam Triadimenol Quinine Tenocixam Triallate Ramipril Terazosine Triamterene Ranitidine Terbinafine Triazolam Raubasine Terbutaline Trifluperazine Reboxetine Terbutryn Trifluperidol Remoxipride Terconazole Triflupromazine Repa glinide Terfenadine Trimethobenzamide Reproterol Tertalolol Trimethoprim Reserpine Tetracaine Trimipramine Riluzole Tetrazepam Tripelennamine 5 Triprolidine Valdecoxib Xipamide Tritoqualine Valsartan Xylometazoline Tromantadine Vardenafil Yohimbine Tropisetron Venlafaxine Zolpidem Trospium Verapamil Zopiclone Tryptamine Vincamine Zuclopenthixol Tulobuterol Warfarin Urapidil Xantinol NEGATIVE MODE: Azelaic Acid Ethyl sulfate 2-Amino -5-nitrobenzophenone Aztreonam Ethyl sulfate -D5 4-Benzamidosalicy clic acid Benserazid Furosemid 5-(p -Methylphenyl) -phenylhydantoin Benzthiazide Hydrochlorothiazide 5-Aminosalicylic acid Bezafibrate Morphin -3ßD -glucuronide -D3 6-Mercaptourine Brallobarbital Pentobarbital Acetazolamide Carbenoxolone Phenobarbital Acetylsalicylic Acid Chl orothiazide Propallylonal Adenine Cimetidine THC -COOH Adenosine Cinchonine THC -OH Adrenalone Cortisone Triamcinolone Alpr ostadil Dinoprost Amobarbital Epinephrine Amoxicillin Ethyl glucuronide Atorvastatin
Load more

Recommended publications
  • R&D UNICANCER Annual Report 2016
    Going further, innovating together R&D UNICANCER Annual Report 2016 Summary Presentation and organisation Regulatory affairs, pharmaco- PAGE 01 vigilance, quality assurance – Ensuring quality and safety 2016 clinical activity in clinical trials. PAGE 08 PAGE 25 Expert groups Epidemiological Strategy and PAGE 16 Medical Economics (ESME) 2016 publications Programme – Harnessing PAGE 21 real-life data in oncology to improve patient care. Clinical operations PAGE 27 PAGE 23 Development Biological Resource and partnerships – Centre (BRC) Optimising collaborations PAGE 24 to foster innovation PAGE 30 Research in the FCCC PAGE 32 Appendices PAGE 33 Contacts, Follow us PAGE 45 GOING FURTHER, INNOVATING TOGETHER R&D ANNUAL REPORT 2016 Presentation and organisation UNICANCER, a major French player in oncology, Acteur majeur de la cancérologie française, groups together 20 French Comprehensive Cancer UNICANCER regroupe les 20 Centres de lutte contre Centers (FCCC). They are private, non-profit health la cancérologie (CLCC), établissements de santé establishments exclusively dedicated to care, research privés à but non lucratif exclusivement dédiés aux and education in cancer. UNICANCER’s R&D soins, à la recherche et à l’enseignement en cancéro- department is the driving force of UNICANCER’s logie. R&D UNICANCER en tant que promoteur research and, as an academic sponsor, it works direc- aca démi que, travaille en direct avec les unités de tly with the research units of the FCCC and other recherche des CLCC et d’autres établissements health establishments (university hospitals, hospitals de santé (CHU, CH, cliniques) en France et à l’inter- and clinics) in France and abroad. The mission of R&D national.
    [Show full text]
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • WO 2018/009638 Al 11 January 2018 (11.01.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/009638 Al 11 January 2018 (11.01.2018) W !P O PCT (51) International Patent Classification: Published: C07D 413/14 (2006.01) A61K 31/553 (2006.01) — with international search report (Art. 21(3)) C07D 403/14 (2006.01) A61P 35/00 (2006.01) — before the expiration of the time limit for amending the (21) International Application Number: claims and to be republished in the event of receipt of PCT/US20 17/040866 amendments (Rule 48.2(h)) (22) International Filing Date: 06 July 2017 (06.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/359,001 06 July 2016 (06.07.2016) 62/454,163 03 February 2017 (03.02.2017) (71) Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN [US/US]; Office Of Technology Tran s fer, 1600 Huron Parkway, 2nd Floor, Ann Arbor, MI 48109-2590 (US). (72) Inventors: ROSS, Brian, D.; 2410 Foxway, Ann Arbor, MI 48105 (US). VAN DORT, Marcian; 643 Dornoch Dr., Ann Arbor, MI 48103 (US). (74) Agent: NAPOLI, James, J.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • Central Valley Toxicology Drug List
    Chloroform ~F~ Lithium ~A~ Chlorpheniramine Loratadine Famotidine Acebutolol Chlorpromazine Lorazepam Fenoprofen Acetaminophen Cimetidine Loxapine Fentanyl Acetone Citalopram LSD (Lysergide) Fexofenadine 6-mono- Clomipramine acetylmorphine Flecainide ~M~ Clonazepam a-Hydroxyalprazolam Fluconazole Maprotiline Clonidine a-Hydroxytriazolam Flunitrazepam MDA Clorazepate Albuterol Fluoxetine MDMA Clozapine Alprazolam Fluphenazine Medazepam Cocaethylene Amantadine Flurazepam Meperidine Cocaine 7-Aminoflunitrazepam Fluvoxamine Mephobarbital Codeine Amiodarone Fosinopril Meprobamate Conine Amitriptyline Furosemide Mesoridazine Cotinine Amlodipine Methadone Cyanide ~G~ Amobarbital Methanol Cyclobenzaprine Gabapentin Amoxapine d-Methamphetamine Cyclosporine GHB d-Amphetamine l-Methamphetamine Glutethamide l-Amphetamine ~D~ Methapyrilene Guaifenesin Aprobarbital Demoxepam Methaqualone Atenolol Desalkylfurazepam ~H~ Methocarbamol Atropine Desipramine Halazepam Methylphenidate ~B~ Desmethyldoxepin Haloperidol Methyprylon Dextromethoraphan Heroin Metoclopramide Baclofen Diazepam Hexobarbital Metoprolol Barbital Digoxin Hydrocodone Mexiletine Benzoylecgonine Dihydrocodein Hydromorphone Midazolam Benzphetamine Dihydrokevain Hydroxychloroquine Mirtazapine Benztropine Diltiazem Hydroxyzine Morphine (Total/Free) Brodificoum Dimenhydrinate Bromazepam ~N~ Diphenhydramine ~I~ Bupivacaine Nafcillin Disopyramide Ibuprofen Buprenorphine Naloxone Doxapram Imipramine Bupropion Naltrexone Doxazosin Indomethacin Buspirone NAPA Doxepin Isoniazid Butabarbital Naproxen
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Us 2018 / 0296525 A1
    UN US 20180296525A1 ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2018/ 0296525 A1 ROIZMAN et al. ( 43 ) Pub . Date: Oct. 18 , 2018 ( 54 ) TREATMENT OF AGE - RELATED MACULAR A61K 38 /1709 ( 2013 .01 ) ; A61K 38 / 1866 DEGENERATION AND OTHER EYE (2013 . 01 ) ; A61K 31/ 40 ( 2013 .01 ) DISEASES WITH ONE OR MORE THERAPEUTIC AGENTS (71 ) Applicant: MacRegen , Inc ., San Jose , CA (US ) (57 ) ABSTRACT ( 72 ) Inventors : Keith ROIZMAN , San Jose , CA (US ) ; The present disclosure provides therapeutic agents for the Martin RUDOLF , Luebeck (DE ) treatment of age - related macular degeneration ( AMD ) and other eye disorders. One or more therapeutic agents can be (21 ) Appl. No .: 15 /910 , 992 used to treat any stages ( including the early , intermediate ( 22 ) Filed : Mar. 2 , 2018 and advance stages ) of AMD , and any phenotypes of AMD , including geographic atrophy ( including non -central GA and Related U . S . Application Data central GA ) and neovascularization ( including types 1 , 2 and 3 NV ) . In certain embodiments , an anti - dyslipidemic agent ( 60 ) Provisional application No . 62/ 467 ,073 , filed on Mar . ( e . g . , an apolipoprotein mimetic and / or a statin ) is used 3 , 2017 . alone to treat or slow the progression of atrophic AMD Publication Classification ( including early AMD and intermediate AMD ) , and / or to (51 ) Int. CI. prevent or delay the onset of AMD , advanced AMD and /or A61K 31/ 366 ( 2006 . 01 ) neovascular AMD . In further embodiments , two or more A61P 27 /02 ( 2006 .01 ) therapeutic agents ( e . g ., any combinations of an anti - dys A61K 9 / 00 ( 2006 . 01 ) lipidemic agent, an antioxidant, an anti- inflammatory agent, A61K 31 / 40 ( 2006 .01 ) a complement inhibitor, a neuroprotector and an anti - angio A61K 45 / 06 ( 2006 .01 ) genic agent ) that target multiple underlying factors of AMD A61K 38 / 17 ( 2006 .01 ) ( e .
    [Show full text]